Why the study?
Does simultaneous analysis of doxorubicin and doxorubicinol in plasma allow for monitoring of doxorubicin toxicity in breast cancer patients?
Does simultaneous analysis of doxorubicin and doxorubicinol in plasma allow for monitoring of doxorubicin toxicity in breast cancer patients?
A simultaneous analytical method successfully measured plasma doxorubicin and doxorubicinol in breast cancer patients, facilitating the monitoring of cumulative doses and associated cardiomyopathy risk.
No takes yet. Share an insight, caveat, or question.
Supports plasma monitoring of doxorubicin exposure in breast cancer; leaves open impact on cardiomyopathy outcomes.
Harahap et al. (2020) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: